GeneFerm Biotechnology Co Ltd Capital Reinvestment Ratio
GeneFerm Biotechnology Co Ltd capital reinvestment ratio. GeneFerm Biotechnology Co Ltd (1796) has a Capital Reinvestment Ratio of 4.13x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$1.45 Million) in capital expenditures (NT$5.98 Million). Check 1796 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of GeneFerm Biotechnology Co Ltd (2017–2024)
Capital reinvestment ratio of GeneFerm Biotechnology Co Ltd from 2017 to 2024. This chart tracks GeneFerm Biotechnology Co Ltd's Capital Reinvestment Ratio across 8 annual periods. Also explore 1796 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
GeneFerm Biotechnology Co Ltd Capital Reinvestment Ratio by Year (2017–2024)
GeneFerm Biotechnology Co Ltd capital reinvestment ratio by year from 2017 to 2024. For the full cash flow conversion analysis, see GeneFerm Biotechnology Co Ltd cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.81x | NT$8.09 Million | NT$22.70 Million | ▲ +647.8% |
| 2023 | 0.38x | NT$190.31 Million | NT$71.40 Million | ▼ -83.5% |
| 2022 | 2.27x | NT$122.43 Million | NT$278.42 Million | ▲ +75.3% |
| 2021 | 1.30x | NT$112.23 Million | NT$145.61 Million | ▼ -11.1% |
| 2020 | 1.46x | NT$56.42 Million | NT$82.32 Million | ▼ -60.7% |
| 2019 | 3.72x | NT$14.69 Million | NT$54.57 Million | ▲ +443.5% |
| 2018 | 0.68x | NT$42.14 Million | NT$28.81 Million | ▼ -24.3% |
| 2017 | 0.90x | NT$61.08 Million | NT$55.16 Million | — |